Elanco Animal Health Incorporated (ELAN) Stock Score, Valuation & Financial Research
Elanco Animal Health Incorporated is in the Healthcare sector and Drug Manufacturers - Specialty & Generic industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 22/100.
Quick answer for ELAN
Elanco Animal Health Incorporated currently has a Wall Street Score of 22/100. The stored market price is $22.86. Its financial score is 24/100. Its valuation score is 0/100. These figures are a research snapshot, not a buy or sell recommendation.
What Elanco Animal Health Incorporated does
Elanco Animal Health, a firm dedicated to animal well-being, creates, produces, and commercializes a diverse array of solutions for both companion animals and livestock. For household pets, the company provides preventative health solutions, including parasiticides and vaccinations, designed to guard against common ailments like worms, fleas, and ticks, with notable brands such as Seresto, Advantage, Advantix, and Advocate. Additionally, Elanco supplies therapeutic treatments for canine and feline conditions including pain, osteoarthritis, ear infections, cardiovascular issues, and dermatological problems, marketed under labels like Galliprant and Claro. Its portfolio for agricultural animals encompasses vaccines, antibiotics, parasiticides, and other essential products for poultry and aquaculture farming. This segment also features nutritional supplements such as enzymes, probiotics, an
ELAN financial snapshot
- Wall Street Score:
- 22/100
- Current price:
- $22.86
- Market capitalization:
- $11.42B
- Revenue:
- $5.02B
- Net income:
- $-199.0M
- Free cash flow:
- $284.0M
- Cash:
- $530.0M
- Total debt:
- $3.92B
- EPS:
- -0.41
- Financial score:
- 24/100
- Valuation score:
- 0/100
- Revenue score:
- 13/100
What stands out
- Reported year-over-year revenue growth is +0.1%.
- Free cash flow is $284.0M, showing positive cash generation.
- The balance sheet shows $530.0M of cash versus $3.92B of total debt, so leverage deserves attention.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 24/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-07.
How to research ELAN
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.